Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Oncolytic viruses
Treatment GMCI(gene-mediated cytotoxic immunotherapy )
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature IFN-γ
Official Symbol IFNG
Mode of action PROT_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Importantly, an increase of IFN-γ was detected onlyin mice receiving GMCI, either alone or ascombination therapy, suggesting an important role of GMCI in inducing an active immune response.
PMID 29016938
Title Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma